The cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab has been authorized for use in advanced, metastatic melanoma in the United States and in the European Union—as in many other countries worldwide since—on basis of two pivotal phase III studies [6, 7]. The gene discussed is CTLA4; the disease is metastatic melanoma.